|
Celldex Therapeutics ، Inc. (CLDX) DCF تقييم
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Celldex Therapeutics, Inc. (CLDX) Bundle
سواء كنت مستثمرًا أو محللًا ، فإن حاسبة DCF (CLDX) هذه هي مورد الخاص بك للتقييم الدقيق. مزودة ببيانات حقيقية من CellDex Therapeutics ، Inc. ، يمكنك ضبط التوقعات ومراقبة التأثيرات في الوقت الحقيقي.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.4 | 4.7 | 2.4 | 6.9 | 7.0 | 7.3 | 7.6 | 7.9 | 8.2 | 8.5 |
| Revenue Growth, % | 0 | -37.3 | -49.32 | 192.02 | 1.99 | 3.84 | 3.84 | 3.84 | 3.84 | 3.84 |
| EBITDA | -45.6 | -66.1 | -104.2 | -139.0 | -191.9 | -7.3 | -7.6 | -7.9 | -8.2 | -8.5 |
| EBITDA, % | -615.3 | -1420.77 | -4420.87 | -2019.96 | -2733.63 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 2.0 | 3.1 | 1.4 | 3.0 | 3.2 | 3.5 | 3.7 | 3.8 | 3.9 | 4.1 |
| Depreciation, % | 26.96 | 65.96 | 59.4 | 43.7 | 45.26 | 48.26 | 48.26 | 48.26 | 48.26 | 48.26 |
| EBIT | -47.6 | -69.1 | -105.6 | -142.0 | -195.1 | -7.3 | -7.6 | -7.9 | -8.2 | -8.5 |
| EBIT, % | -642.26 | -1486.73 | -4480.27 | -2063.66 | -2778.89 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 194.4 | 408.3 | 305.0 | 423.6 | 725.3 | 7.3 | 7.6 | 7.9 | 8.2 | 8.5 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1.8 | .2 | .3 | 2.6 | .7 | 1.3 | 1.4 | 1.4 | 1.5 | 1.5 |
| Account Receivables, % | 24.29 | 3.7 | 14.72 | 38.18 | 9.97 | 18.17 | 18.17 | 18.17 | 18.17 | 18.17 |
| Inventories | -1.8 | -.2 | -.3 | .0 | .0 | -.6 | -.6 | -.7 | -.7 | -.7 |
| Inventories, % | -24.29 | -3.7 | -14.72 | 0 | 0 | -8.54 | -8.54 | -8.54 | -8.54 | -8.54 |
| Accounts Payable | 1.0 | 1.2 | 3.3 | 3.5 | 3.3 | 3.5 | 3.6 | 3.7 | 3.9 | 4.0 |
| Accounts Payable, % | 14.13 | 26.4 | 141.71 | 50.76 | 46.51 | 47.56 | 47.56 | 47.56 | 47.56 | 47.56 |
| Capital Expenditure | -1.6 | -1.2 | -1.8 | -1.8 | .0 | -2.2 | -2.3 | -2.4 | -2.5 | -2.6 |
| Capital Expenditure, % | -20.92 | -26.85 | -77.56 | -26.41 | 0 | -30.35 | -30.35 | -30.35 | -30.35 | -30.35 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -46.7 | -68.9 | -115.4 | -142.0 | -195.1 | -7.3 | -7.5 | -7.8 | -8.1 | -8.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -45.2 | -66.9 | -113.7 | -143.3 | -190.2 | -5.8 | -6.1 | -6.3 | -6.5 | -6.8 |
| WACC, % | 11.55 | 11.55 | 11.55 | 11.55 | 11.55 | 11.55 | 11.55 | 11.55 | 11.55 | 11.55 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -22.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -7 | |||||||||
| Terminal Value | -73 | |||||||||
| Present Terminal Value | -42 | |||||||||
| Enterprise Value | -65 | |||||||||
| Net Debt | -25 | |||||||||
| Equity Value | -40 | |||||||||
| Diluted Shares Outstanding, MM | 64 | |||||||||
| Equity Value Per Share | -0.63 |
What You Will Get
- Real Celldex Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Celldex Therapeutics, Inc. (CLDX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specific to Celldex.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Celldex’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections for Celldex Therapeutics, Inc. (CLDX).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility in your analysis of Celldex.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Celldex Therapeutics, Inc. (CLDX).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Adjust growth projections, capital investments, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Celldex Therapeutics, Inc. (CLDX).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis.
How It Works
- 1. Access the Template: Download and open the Excel file featuring Celldex Therapeutics, Inc. (CLDX) preloaded data.
- 2. Adjust Assumptions: Modify key inputs such as growth rates, WACC, and capital expenditures tailored to Celldex Therapeutics, Inc. (CLDX).
- 3. View Results Instantly: The DCF model automatically calculates the intrinsic value and NPV for Celldex Therapeutics, Inc. (CLDX).
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation outcomes for Celldex Therapeutics, Inc. (CLDX).
- 5. Present with Confidence: Share professional valuation insights to bolster your decision-making regarding Celldex Therapeutics, Inc. (CLDX).
Why Choose Celldex Therapeutics, Inc. (CLDX) Calculator?
- All-in-One Solution: Features DCF, WACC, and financial ratio analyses tailored for biotech investments.
- Flexible Inputs: Modify highlighted cells to explore different investment scenarios.
- In-Depth Analysis: Automatically computes Celldex’s intrinsic value and Net Present Value.
- Preloaded Information: Access to historical and projected data for reliable assessments.
- Expert-Level Tool: Perfect for financial analysts, investors, and healthcare consultants.
Who Should Use This Product?
- Biotech Students: Explore drug development processes and apply theoretical knowledge to real-world scenarios.
- Researchers: Integrate advanced models into your studies on immunotherapy and cancer treatments.
- Investors: Evaluate your investment strategies and analyze the market performance of Celldex Therapeutics, Inc. (CLDX).
- Market Analysts: Enhance your analysis with a customizable model tailored for biotech companies.
- Healthcare Entrepreneurs: Understand the valuation methods used for emerging biotech firms like Celldex Therapeutics, Inc. (CLDX).
What the Template Contains
- Pre-Filled DCF Model: Celldex Therapeutics’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Celldex’s profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.